IP Library Granted Patent US 8,017,627
Granted Patent B2
US 8,017,627 · App. 10/343,449 · Granted Sep 13, 2011

Fentanyl composition for nasal administration

Assignee: Nycomed Danmark APS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,627
App. No.
10/343,449
Granted
Sep 13, 2011
Kind
B2
Abstract

The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions for use in the method are also disclosed.

Claims (24)

1. A method for the treatment of pain in a mammal, which comprises intranasally administering, by a nasal spray to the nasal mucosal membrane of said mammal, at least a single dosage unit having a volume of 10 to 200 μl in one administration by one delivery operation comprising a fentanyl salt in an amount equivalent to 70 to 500 μg of fentanyl in a solvent comprising water, to deliver a treatment dosage of from 70 to 1000 μg of fentanyl until a time-to-onset-of-action, said dosage unit being in the form of a composition having a concentration equivalent to about 0.4 to 75 mg/ml of fentanyl.

2. The method according to claim 1 , wherein said administration comprises the delivery of at least a single dosage unit equivalent to 75 to 300 μg of fentanyl.

3. The method according to claim 1 , wherein said administration comprises the delivery of at least a single dosage unit equivalent to 75 μg fentanyl.

4. The method according to claim 1 wherein the mammal is a human.

5. The method according to claim 1 wherein said administration comprises the delivery of at least a single dosage unit equivalent to 100 μg fentanyl.

6. The method according to claim 1 wherein said administration comprises the delivery of at least a single dosage unit equivalent to 150 μg of fentanyl.

7. The method according to claim 1 wherein said administration comprises the delivery of at least a single dosage unit equivalent to 200 μg of fentanyl.

8. The method according to claim 1 , wherein said fentanyl salt is fentanyl citrate.

9. The method according to claim 1 , wherein said solvent further comprises isotonic saline, polyethylene glycol, or a combination thereof.

10. The method according to claim 1 , wherein said solvent comprises about 95%-100% water.

11. The method according to claim 9 wherein said single dosage unit consists essentially of fentanyl salt and said solvent.

12. The method according to claim 1 wherein the treatment is alleviation or lessening of acute or breakthrough pain.

13. The method according to claim 1 wherein the mammal further receives an analgesic.

14. The method according to claim 13 , wherein the analgesic is fentanyl, or a salt thereof.

15. The method according to claim 12 wherein said acute or breakthrough pain comprises colic/biliary pain, trauma, postoperative pain, dental pain, orofacial pain, sympathetic pain syndrome, pancreatic pain, myocardial infarction pain, cancer pain, back pain, or pain during or after change of dressing.

16. The method according to claim 1 wherein said method is for pre-operative anesthesia.

17. The method according to claim 1 wherein said administration comprises the delivery of at least a single dosage unit equivalent to 400 μg of fentanyl.

18. The method of claim 17 wherein the treatment is alleviation or lessening of breakthrough pain.

19. The method according to claim 1 , wherein the volume of the single dosage unit is 50 to 150 μl.

20. The method according to claim 1 , wherein the single dosage unit is in the form of a composition having a concentration equivalent to about 0.5 to 20 mg/ml of fentanyl.

21. The method according to claim 1 , wherein the single dosage unit is in the form of a composition having a concentration equivalent to about 0.6 to 15 mg/ml of fentanyl.

22. The method according to claim 1 , wherein the single dosage unit is in the form of a composition having a concentration equivalent to about 0.7 to 12 mg/ml of fentanyl.

23. The method according to claim 1 , wherein the single dosage unit is in the form of a composition having a concentration equivalent to about 0.75 to 10 mg/ml of fentanyl.

24. The method according to claim 1 , wherein the single dosage unit is in the form of a composition having a concentration equivalent to about 0.75 to 8 mg/ml of fentanyl.

Assignments (5)
CHANGE OF ADDRESS Recorded Mar 2, 2022
From: TAKEDA PHARMA A/S
To: TAKEDA PHARMA A/S
Reel/Frame 059289/0393 →
CHANGE OF ADDRESS Recorded Feb 11, 2016
From: TAKEDA PHARMA A/S
To: TAKEDA PHARMA A/S
Reel/Frame 037785/0997 →
CHANGE OF NAME Recorded Aug 14, 2013
From: NYCOMED DANMARK APS
To: TAKEDA PHARMA A/S
Reel/Frame 031014/0049 →
CHANGE OF NAME Recorded May 7, 2009
From: NYCOMED DANMARK A/S
To: NYCOMED DANMARK APS
Reel/Frame 022660/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2003
From: GRARUP, JESPER; NIELSEN, HANNE WULF
To: NYCOMED DANMARK A/S
Reel/Frame 014265/0747 →
Priority Claims (1)
DK 2000 01154 · Jul 31, 2000 · national
Continuity (1)
Related Publication 20040034059A1 · Feb 19, 2004